These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 27993410)

  • 21. Patients' and providers' perspectives of a polypill strategy to improve cardiovascular prevention in Australian primary health care: a qualitative study set within a pragmatic randomized, controlled trial.
    Liu H; Massi L; Laba TL; Peiris D; Usherwood T; Patel A; Cass A; Eades AM; Redfern J; Hayman N; Howard K; Brien JA; Jan S
    Circ Cardiovasc Qual Outcomes; 2015 May; 8(3):301-8. PubMed ID: 25944629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?
    Franczyk B; Gluba-Brzózka A; Jurkiewicz Ł; Penson P; Banach M; Rysz J
    Expert Opin Pharmacother; 2018 Dec; 19(17):1857-1865. PubMed ID: 30295098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strengths and Limitations of Using the Polypill in Cardiovascular Prevention.
    Roy A; Naik N; Srinath Reddy K
    Curr Cardiol Rep; 2017 May; 19(5):45. PubMed ID: 28425033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The polypill: An effective approach to increasing adherence and reducing cardiovascular event risk.
    Bramlage P; Sims H; Minguet J; Ferrero C
    Eur J Prev Cardiol; 2017 Feb; 24(3):297-310. PubMed ID: 27798363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The cardiovascular polypill in high-risk patients.
    Lafeber M; Spiering W; Singh K; Guggilla RK; Patil V; Webster R;
    Eur J Prev Cardiol; 2012 Dec; 19(6):1234-42. PubMed ID: 22019908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of the polypill for secondary prevention in ischaemic heart disease.
    Castellano JM; Fuster V; Jennings C; Prescott E; Bueno H
    Eur J Prev Cardiol; 2017 Jun; 24(3_suppl):44-51. PubMed ID: 28618914
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Benefits of the Polypill on Medication Adherence in the Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review.
    Lopez-Lopez JP; Gonzalez AM; Lanza P; Lopez-Jaramillo P
    Vasc Health Risk Manag; 2023; 19():605-615. PubMed ID: 37719697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polypill Strategy in Secondary Cardiovascular Prevention.
    De la Rosa A; Arrington K; Desai R; Acharya PC
    Curr Cardiol Rep; 2024 May; 26(5):443-450. PubMed ID: 38557814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fixed-dose combination treatment after stroke for secondary prevention in China: a national community-based study.
    Longde W; Ling Y; Yang H; Yi Z; Yongjun W; Xunming J; Xiaoyuan N; Qiumin Q; Li H; Yuming X; Mei L; Jiayi S; Jing L; Dong Z
    Stroke; 2015 May; 46(5):1295-300. PubMed ID: 25782466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease.
    Lafeber M; Webster R; Visseren FLj; Bots ML; Grobbee DE; Spiering W; Rodgers A;
    Eur J Prev Cardiol; 2016 Aug; 23(12):1289-97. PubMed ID: 26743587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polypill: an affordable strategy for cardiovascular disease prevention in low-medium-income countries.
    López-Jaramillo P; González-Gómez S; Zarate-Bernal D; Serrano A; Atuesta L; Clausen C; Castro-Valencia C; Camacho-Lopez P; Otero J
    Ther Adv Cardiovasc Dis; 2018 Jun; 12(6):169-174. PubMed ID: 29546816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Impact of the Polypill for Cardiovascular Prevention in Latin America: A Consensus Statement of the Inter-American Society of Cardiology.
    Sosa-Liprandi Á; Sosa Liprandi MI; Alexánderson E; Avezum Á; Lanas F; López-Jaramillo JP; Martínez F; Ponte-Negretti N CI; Wyss F; González Juanatey JR; Perel P
    Glob Heart; 2019 Mar; 14(1):3-16.e1. PubMed ID: 30502220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The polypill in cardiovascular prevention: successful through simplification? : New study results on the benefit of the polypill strategy in primary and secondary prevention].
    Despang P; Schikora M; Doehner W
    Inn Med (Heidelb); 2023 Jun; 64(6):598-604. PubMed ID: 37227456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Polypill: From Promise to Pragmatism.
    Huffman MD
    PLoS Med; 2015 Aug; 12(8):e1001862. PubMed ID: 26263422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient preferences for a polypill for the prevention of cardiovascular diseases.
    Laba TL; Howard K; Rose J; Peiris D; Redfern J; Usherwood T; Cass A; Patel A; Jan S
    Ann Pharmacother; 2015 May; 49(5):528-39. PubMed ID: 25680761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A practical approach to switch from a multiple pill therapeutic strategy to a polypill-based strategy for cardiovascular prevention in patients with hypertension.
    Coca A; Kreutz R; Manolis AJ; Mancia G
    J Hypertens; 2020 Oct; 38(10):1890-1898. PubMed ID: 32890261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The polypill strategy in cardiovascular disease prevention: It's time for its implementation.
    Di Fusco SA; Aquilani S; Spinelli A; Alonzo A; Matteucci A; Castello L; Imperoli G; Colivicchi F
    Prog Cardiovasc Dis; 2023; 79():37-40. PubMed ID: 36931543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The value of the polypill in cardiovascular disease: an Italian multidisciplinary Delphi panel consensus.
    Perrone-Filardi P; Minghetti P; Menditto E; Bianchi S; Scaglione F; Trifirò G; Piccinocchi G; Corona T; Gambarelli G; Izzi C; Misciagna V; Putignano D; Lopatriello S; Cafiero D
    J Cardiovasc Med (Hagerstown); 2021 Apr; 22(4):246-258. PubMed ID: 33633039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
    Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
    Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polypill: quo vadis?
    Muscente F; De Caterina R
    J Cardiovasc Med (Hagerstown); 2016 Nov; 17(11):783-92. PubMed ID: 27341194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.